WALTHAM, Mass., June 3, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has received approval from the U.S. Food and Drug Administration (“FDA”) to initiate its photorefractive keratectomy (“PRK”) pivotal study. The FDA has determined that EyeGate provided sufficient data to support initiation of the clinical study and…
WALTHAM, Mass., May 22, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received its first development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”) under the…
Company Plans to Initiate Randomized, Double-masked, Placebo-Controlled Study in First Half of 2017 WALTHAM, Mass., Dec. 05, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced promising data from the third…
WALTHAM, Mass., January 14, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble…
WALTHAM, Mass., January 24, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial…
Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase WALTHAM, Mass., Jan. 04, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, today announced the promotion of Sarah Romano from…
WALTHAM, Mass., March 02, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has received an additional development milestone from Valeant Pharmaceuticals Luxembourg S.à.r.l. (“Valeant”) under the Company’s License…
WALTHAM, MA., August 3, 2018 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three month period ended June 30, 2018, and provided an update on recent corporate and operational…
WALTHAM, Mass., Nov. 02, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2016, and provided an update on recent corporate and operational…
WALTHAM, Mass., Nov. 14, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2017, and provided an update on recent corporate and operational activities.…